InflaRx shares surge 28.46% premarket amid anticipation of Phase 2a INF904 trial results and Q3 financials release.

InflaRx N.V. (IFRX) surged 28.46% in premarket trading following anticipation of positive Phase 2a clinical trial results for its lead candidate, INF904. The stock’s sharp rise aligns with news of the upcoming release of topline data for INF904 in hidradenitis suppurativa and chronic spontaneous urticaria, which could validate its anti-inflammatory pipeline and attract investor interest. Recent reports highlighted the trial results as a potential catalyst to reverse the stock’s prior 17.81% weekly decline and reinforce its strategic positioning in niche autoimmune therapies. While financial metrics remain weak, the focus on near-term clinical milestones and key opinion leader engagement during a webcast presentation amplified short-term optimism. The premarket rally reflects market positioning ahead of the data disclosure, with traders capitalizing on the biotech’s high volatility and potential for renewed momentum.